Department of Neurosurgery, The Second Hospital of Hebei Medical University, Hebei, China.
Medicine (Baltimore). 2024 May 10;103(19):e38066. doi: 10.1097/MD.0000000000038066.
CDCA3, a cell cycle regulator gene that plays a catalytic role in many tumors, was initially identified as a regulator of cell cycle progression, specifically facilitating the transition from the G2 phase to mitosis. However, its role in glioma remains unknown. In this study, bioinformatics analyses (TCGA, CGGA, Rembrandt) shed light on the upregulation and prognostic value of CDCA3 in gliomas. It can also be included in a column chart as a parameter predicting 3- and 5-year survival risk (C index = 0.86). According to Gene Set Enrichment Analysis and gene ontology analysis, the biological processes of CDCA3 are mainly concentrated in the biological activities related to cell cycle such as DNA replication and nuclear division. CDCA3 is closely associated with many classic glioma biomarkers (CDK4, CDK6), and inhibitors of CDK4 and CDK6 have been shown to be effective in tumor therapy. We have demonstrated that high expression of CDCA3 indicates a higher malignancy and poorer prognosis in gliomas.
CDCA3 是一种细胞周期调控基因，在许多肿瘤中具有催化作用，最初被鉴定为细胞周期进程的调控因子，特别是促进从 G2 期向有丝分裂的过渡。然而，它在神经胶质瘤中的作用尚不清楚。在这项研究中，生物信息学分析（TCGA、CGGA、Rembrandt）揭示了 CDCA3 在神经胶质瘤中的上调和预后价值。它也可以作为预测 3 年和 5 年生存风险的参数（C 指数=0.86）包含在柱形图中。根据基因集富集分析和基因本体论分析，CDCA3 的生物学过程主要集中在与细胞周期相关的生物活性中，如 DNA 复制和核分裂。CDCA3 与许多经典的神经胶质瘤生物标志物（CDK4、CDK6）密切相关，CDK4 和 CDK6 的抑制剂已被证明在肿瘤治疗中有效。我们已经证明，CDCA3 的高表达表明神经胶质瘤的恶性程度更高，预后更差。
